5 / 22
Page 27
Notes:
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Biotechnol Biomater, an open access journal
ISSN: 2155-952X
Bio America 2017
October 19-20, 2017
October 19-20, 2017 | New York, USA
18
th
Biotechnology Congress
Human induced pluripotent stem cells are invaluable tools in the investigation of
in-vitro
disease modeling,
drug testing, and
in-vivo
cell replacement therapies
Sima T Tarzami
Howard University, USA
A
n adult heart has an intrinsically limited capability to regenerate damaged myocardium, regardless of the underlying etiology.
Embryonic and induced pluripotent stem cell (ESC/iPSC)- based therapies offer a unique strategy for developing cell replacement
therapies for numerous, varied disorders including cardiac diseases. iPSCs hold great promise in the field of regenerative medicine
because of their ability to grow indefinitely and give rise to all cells of the body. Both ESC and iPSCs have been invaluable tools in
the investigation of
in-vitro
disease modeling, drug testing, and
in-vivo
cell replacement therapies. The major advantages of iPSCs
for cell transplantation are that these cells are patient-specific, thereby reducing the risk for graft rejection and secondly, evade
the moral and ethical issues concerning ESCs. Human iPSCs have now been generated from several human tissues using a variety
of approaches. Most commonly, human iPSCs are generated from dermal fibroblasts due to their accessibility and relatively high
efficiency of reprogramming. Many doctors are exploring the use of stem cell therapy for many diseases including neurodegenerative,
diabetes, rheumatological and hematological disease. Even though iPSCs have been used in preclinical animal models of cardiac
failure with promising results, but it still has many limitations. Recently investigators shown that pluripotent stem cells produce
tissue-specific lineages through the programmed acquisition of sequential gene expression patterns that function as a road map for
organ formation, therefore, identifying a procardiogenic network that promotes iPSCs differentiation to favor a cardiac lineage is of
great interest. Since adult human hearts have very little ability to regenerate postnatally, stem-cell-based cardiac regeneration has also
been considered as a therapeutic approach to treat ischemic heart disease. Since these cells have been shown to migrate to sites of
injury and inflammation in response to soluble mediators including the chemokine stromal cell derived factor-1 (SDF-1 also known
as CXCL12). Here we studied the role of SDF-1 and its receptors; CXCR4 and CXCR7 in transformation of pluripotent stem cells into
IPSC-derived cardiomyocytes and also in SDF-1-directed migration of IPSCs with the premise that their improved recruitment could
translate to therapeutic benefits
Biography
Sima T Tarzami is currently the Assistant Professor in Howard University, USA.
sima.tarzami@howard.eduSima T Tarzami, J Biotechnol Biomater 2017, 7:4 (Suppl)
DOI: 10.4172/2155-952X-C1-079